

To: (10)(2e) (10)(2e) (10)(2e) @rivm.nl; (10)(2e) (10)(2e) (10)(2e) @rivm.nl
From: (10)(2e) (10)(2e) (10)(2e)
Sent: Thur 4/16/2020 3:06:28 PM
Subject: RE: update VITAL- impact COVID-19 pandemic
Received: Thur 4/16/2020 3:08:16 PM

I was hoping that the slides are good to use already so won't need much more work?

I will ask about others getting involved in my WP4 work and Pfizer representation

(10)(2e)

From: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>
Sent: 16 April 2020 15:34
To: (10)(2e) (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) (10)(2e) (10)(2e) <(10)(2e)@pfizer.com>
Subject: [EXTERNAL] update VITAL- impact COVID-19 pandemic

Dear (10)(2e) and (10)(2e),

I have attended two VITAL TC to assess the impact of COVID-19 on the VITAL project. In the last 4VITAL TC, (10)(2e) you discussed the impact for 4VITAL and I have presented this.

To give you an update on what has been discussed:

General:

- IMI is looking at an extension of 6 months for the VITAL project, however WP 1 for example should need one extra year because of seasonality.
- We need to think about whether we need extra resources because of this extension?

4VITAL specific:

- The HCP professional study will most likely be delayed, because the inclusion of HCP is currently impossible. Also, ethical committees in Hungary and Italy are postponed or suspended. Adjustments to the topic list and questionnaire are made to make the submission of study documents less complicated. And project partners are also busy with VITAL.
- We will add specific COVID questions to the study about the perspective towards vaccinations for elderly and themselves.
- For now, the focus is on the two systematic reviews and the analysis of the focus group study. (10)(2e) asked whether the PhD of (10)(2e) is on track and I think it is.
- It was asked how much delay we expected, this is difficult because we don't know when this pandemic will end and HCP will be available. It suggested by (10)(2e) that we should provide IMI with a rolling start planning. So; if tomorrow, everything would be back to normal, how much time do we need to get the study started. I will think about this.
- The questions we included in WP2 give us an opportunity to have a before and after measurement on the contacts with HCP. So, this is interesting.

And then I think the most important thing that was asked: Do we have a plan B when, worst case scenario, the HCP can not be conducted. This is difficult because we really need the HCP. Plan B could look at the literature. I will think about this too.

(10)(2e): (10)(2e) asked me whether there is a replacement for you in general and for your involvement in the developing of the VITAL slides: Is there anyone who can contribute?

All the best,

(10)(2e)

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to *health and sustainability*